Among all identified protein, transthyretin (TTR) has been validated to elucidate its differential level consistency in CAD because TTR is well known as an acute-phase reactant protein, whose wild-type transthyretin amyloidosis variant expression has been observed to be reduced during the inflammatory response of familial amyloidotic polyneuropathy (FAP) and biopsy-proven amyloidosis [20]. Here, TTR is linked to coronary artery disorder.